|
Major Depressive Disorder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that CYP2D6 ultra-rapid metabolizer status contributes to venlafaxine-XR treatment remission in MDD patients; in particular, there is a PK-PD interaction with treatment remission associated with CYP2D6 URM phenotype and SLC6A4 5-HTTLPR L/L or SLC6A2 G1287A G/A genotype, respectively.
|
30578947 |
2019 |
|
Major Depressive Disorder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Influence of the cytochrome P450 2D6 *10/*10 genotype on the pharmacokinetics of paroxetine in Japanese patients with major depressive disorder: a population pharmacokinetic analysis.
|
27187662 |
2016 |
|
Major Depressive Disorder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
CYP-GUIDES (Cytochrome Psychotropic Genotyping Under Investigation for Decision Support) is a randomized controlled trial (RCT) comparing 2 outcomes in hospitalized patients with major depressive disorder (MDD) treated according to the patient's CYP2D6 genotype and functional status versus standard psychotropic therapy.
|
31838256 |
2019 |
|
Major Depressive Disorder
|
0.500 |
Biomarker
|
disease |
BEFREE |
Impact of CYP2D6 on venlafaxine metabolism in Trinidadian patients with major depressive disorder.
|
29327975 |
2018 |
|
Major Depressive Disorder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The risk of major depression in CYP2D6*4/*4 was not significantly different from extensive metabolizers (OR = 0.85; 95% CI: 0.36-2.00; p = 0.72).
|
19374513 |
2009 |
|
Major Depressive Disorder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
CYP2C9, CYP2C19 and CYP2D6 genotypes and clinical data were obtained for 150 consecutive, consenting hospital admissions with a diagnosis of major depressive disorder and who were treated with psychotropic medications.
|
21861666 |
2011 |
|
Major Depressive Disorder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A total of 149 inpatients with a diagnosis of major depressive disorder at the Institute of Living, Hartford Hospital (CT, USA), were genotyped to detect altered alleles in the CYP2D6 gene.
|
23734807 |
2013 |
|
Major Depressive Disorder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This paper explores the link between CYP2D6 genotype and antidepressant-associated ADRs in outpatients being treated for major depression with either nortriptyline or fluoxetine.
|
14716707 |
2004 |
|
Major Depressive Disorder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk-a European multicentre study on treatment-resistant major depressive disorder.
|
23081704 |
2013 |
|
Major Depressive Disorder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The objective of this study is to investigate the influence of the 5-HTTLPR (serotonin transporter-linked promoter region), cytochrome P450 2C19, and cytochrome P450 2D6 polymorphisms on escitalopram (ESC) and venlafaxine (VEN) responses in major depressive disorder.
|
24014145 |
2013 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
With respect to CYP2D6*4 polymorphism, significantly increased risk of AD was found in allelic contrast model of A vs. G (OR=1.29, 95%CI=1.03-1.62, P=0.026), co-dominant genetic model AA vs. GG (OR=1.91, 95%CI=1.04-3.51, P=0.038); and recessive genetic model AA vs. AG+GG (OR=1.88, 95%CI=1.03-3.46, P=0.041) in the overall populations.
|
24909950 |
2014 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study explored the influence of apolipoprotein E3 and CYP2D6 (rs1065852) gene polymorphisms on therapeutic responses to donepezil in Han Chinese patients with Alzheimer's disease.
|
26768225 |
2016 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We genotyped 86 subjects with diagnoses of probable AD to determine if they carried the alpha-1-antichymotrypsin (ACT) A allele, which has been associated with AD, or the CYP2D6 B mutant, found at increased frequency in the Lewy body variant (LBV) of AD.
|
8916107 |
1996 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
About 57.76% of patients with Alzheimer's disease are extensive metabolisers (EMs) for CYP2D6 enzymes, 31.06% are intermediate metabolisers (IMs), 5.28% are poor metabolisers (PMs), and 5.90% are ultrarapid metabolisers (UMs); 73.71% are CYP2C19-EMs, 25.12% IMs, and 1.16% PMs; 60.87% are CYP2C9-EMs, 34.16% IMs, and 4.97% PMs; 82.75% are CYP3A4/5-EMs, 15.88% IMs, and 1.37% UMs.
|
20197699 |
2010 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Both univariate and multiple linear regression analysis indicated that only <i>CYP2D6*10</i> allele was associated with higher Cpss (<i>p</i>-value =0.029 and B =0.478, <i>p</i>-value =0.032, respectively) that might influence the clinical outcomes of donepezil. ie, TMSE (<i>p</i>-value =0.010 and B =4.527, <i>p</i>-value =0.001) and ΔTMSE (<i>p</i>-value =0.023 and B =4.107, <i>p</i>-value =0.002), especially in patients with AD.
|
31564952 |
2019 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Also, due to such a rare occurrence of the CYP2D6*4 polymorphism, we can not confirm the protective role of the polymorphism against AD in the Korean population.
|
11442888 |
2001 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The AD susceptibility gene cholesterol 25-hydroxylase (<i>CH25H</i>) is upregulated in the AD brain and is involved in the antiviral immune response.
|
29559905 |
2018 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
AD patients with mutant allele (*10) in CYP2D6 gene may respond better to donepezil than those with wild allele (*1).
|
22986607 |
2013 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study evaluated CYP2D6 polymorphisms to elucidate the stereoselective metabolism of donepezil and to confirm the association between the steady-state plasma concentrations of the pharmaco-effective S-donepezil and the therapeutic responses of Han Chinese patients with Alzheimer's disease.
|
26603528 |
2015 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The analysis of CYP2D6 genotypes may be useful in identifying subgroups of patients with AD who have different clinical responses to donepezil.
|
19738170 |
2009 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cholesterol 25-hydroxylase on chromosome 10q is a susceptibility gene for sporadic Alzheimer's disease.
|
16909003 |
2005 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Therefore, we compared frequencies of CYP2D6*3, *4, and *10 mutant alleles in 17 Japanese DLB patients to those among Alzheimer-type dementia (ATD) patients and healthy controls.
|
11285084 |
2001 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of the study was to examine the genetic polymorphism in cytochrome P450 2D6 (CYP2D6) and glutathione S-transferases pi 1 (GSTP1) with respect to organochlorine pesticides (OCPs) and metals in AD.
|
24584466 |
2014 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Pharmacogenomics studies also indicate that the therapeutic response in AD is genotype-specific and that approximately 15% of the cases with efficacy and/or safety problems are associated with a defective CYP2D6 gene.
|
12943467 |
2003 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated the association of Parkinson's disease (PD) with two genes encoding liver-detoxifying enzymes, debrisoquine 4-hydroxylase (CYP2D6) and N-acetyltransferase 2 (NAT2), and with one gene related to Alzheimer's disease, apolipoprotein E (APOE).
|
10928584 |
2000 |